Preventing the Hypoxia-Adenosinergic Inhibtion of Anti-HIV Immune Response

防止缺氧腺苷能抑制抗 HIV 免疫反应

• 批准号: 8516452
• 负责人: Michail Sitkovsky
• 金额: $ 25.19万
• 依托单位: DANA-FARBER CANCER INST
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/8516452
• 关键词: Acquired Immunodeficiency Syndrome; Acute; Adenosine; Adjuvant; Antibodies; B-Lymphocytes; Caffeine; Cells; Effectiveness; Epidemic; HIV; HIV Antibodies; HIV Envelope Protein gp41; HIV Infections; HIV vaccine; HIV-1; Human; Hypoxia; Immune response; Immunoglobulin M; Infection; Medical; Pharmaceutical Preparations; Proteins; Public Health; Recombinant Vaccines; T cell response; T-Lymphocyte; Translating; Vaccination; cell mediated immune response; drug testing; improved; innovation; neutralizing antibody; novel; novel strategies; prevent; receptor function; vaccination strategy

It is believed that innovative adjuvants might be capable of inducing higher titers of broadly neutralizing anti-HIV-1 antibodies and better anti-HIV-1 T-cell responses. We propose to explore a novel opportunity to improve the effectiveness of anti-HIV vaccines by using anti-adenosinergic

据认为，创新的佐剂可能能够诱导更高的中和抗HIV-1抗体和更好的抗HIV-1 T细胞反应的较高的滴度。我们建议探索一种新的机会，通过使用抗腺苷能量来提高抗HIV疫苗的有效性